Sanara MedTech’s (SMTI) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sanara MedTech (NASDAQ:SMTI) in a research report released on Monday,Benzinga reports. They currently have a $36.00 price target on the stock. HC Wainwright also issued estimates for Sanara MedTech’s FY2025 earnings at $0.20 EPS, Q1 2026 earnings at $0.13 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.17 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.65 EPS.

A number of other equities research analysts have also issued reports on the company. Wall Street Zen lowered Sanara MedTech from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Zacks Research cut Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $41.00.

Sanara MedTech Price Performance

NASDAQ SMTI opened at $21.38 on Monday. The company has a current ratio of 1.80, a quick ratio of 1.60 and a debt-to-equity ratio of 7.34. Sanara MedTech has a 12 month low of $18.90 and a 12 month high of $37.91. The stock has a market cap of $190.28 million, a price-to-earnings ratio of -5.07 and a beta of 1.06. The company’s 50 day moving average is $22.88 and its two-hundred day moving average is $27.18.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.33. The firm had revenue of $26.33 million during the quarter, compared to analysts’ expectations of $26.63 million. Sanara MedTech had a negative net margin of 36.79% and a negative return on equity of 21.33%. As a group, research analysts anticipate that Sanara MedTech will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On Sanara MedTech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SMTI. BNP Paribas Financial Markets increased its stake in Sanara MedTech by 351.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock worth $48,000 after acquiring an additional 1,171 shares during the last quarter. Lazard Asset Management LLC grew its holdings in shares of Sanara MedTech by 63,100.0% in the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock valued at $89,000 after purchasing an additional 3,155 shares in the last quarter. Bank of America Corp DE increased its position in Sanara MedTech by 44.1% in the third quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock worth $101,000 after purchasing an additional 973 shares during the last quarter. Rhumbline Advisers raised its stake in Sanara MedTech by 14.9% during the first quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after purchasing an additional 483 shares in the last quarter. Finally, Salem Investment Counselors Inc. raised its stake in Sanara MedTech by 25.0% during the fourth quarter. Salem Investment Counselors Inc. now owns 10,897 shares of the company’s stock valued at $254,000 after purchasing an additional 2,182 shares in the last quarter. 8.10% of the stock is owned by institutional investors.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.